A phase 3 trial reveals that survodutide, an experimental injection, can significantly reduce weight and improve blood sugar levels in adults with obesity or type 2 diabetes, though side effects may limit its use.
An experimental weekly injection called survodutide helped adults with obesity or overweight and type 2 diabetes lose as much as 13.1% of their body weight over 76 weeks, according to results published in The New England Journal of Medicine and presented at the European Association for the Study of Diabetes annual meeting. The findings suggest the drug may one day add another option for a group of patients who often need treatments that address both weight and blood sugar at the same time, although survodutide is still under investigation and is not approved for use.
The phase 3 SYNCHRONIZE-2 trial enrolled 755 adults and compared two doses of survodutide, 3.6 mg and 6.0 mg, with placebo. Boehringer Ingelheim, which is developing the drug, said the study met its main goals. The company reported that up to 79.3% of participants taking survodutide lost at least 5% of their body weight, while the placebo group did far less well. Average HbA1c, a standard measure of long-term blood sugar, fell by as much as 1.21 percentage points from a starting level of 7.4%, compared with almost no change on placebo.
The trial also showed a notable limitation: stomach-related side effects led 18% of patients on survodutide to stop treatment, compared with 1.2% on placebo. Nausea, vomiting, diarrhoea and constipation were the main reasons people discontinued the drug, and most of those withdrawals happened while doses were being increased. That matters because tolerability often determines whether a diabetes-and-weight-loss treatment can be used in routine care, particularly for people already managing several medications.
Survodutide works differently from currently approved GLP-1 medicines because it activates both the GLP-1 receptor and the glucagon receptor. GLP-1 drugs slow stomach emptying, reduce appetite and help the body release insulin after meals, while glucagon can increase energy use and affect the liver. That dual action has also prompted the company to study survodutide in metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease. In a separate earlier trial in people with obesity or overweight but without type 2 diabetes, survodutide produced larger average weight loss, reinforcing the pattern that diabetes can make weight reduction harder to achieve even with potent drugs.
The results are encouraging, but they do not change treatment today. The trial measured weight and blood sugar, not heart attacks, strokes or deaths, and a cardiovascular outcomes study is still under way. Comparisons with approved medicines such as semaglutide and tirzepatide remain uncertain because those drugs were tested in different populations and studies. For now, survodutide remains experimental, no regulatory filing date has been announced, and people with type 2 diabetes should not alter their current treatment plans on the basis of these data alone.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
